Sunshine Biopharma Inc Financials
Sunshine Biopharma Inc (SBFM) reported $36.3M in revenue for fiscal year 2025, up 4.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is rising, but overhead still outruns product economics, leaving the business reliant on cash rather than operating self-funding.
The least obvious shift is that cash consumption improved sharply even while reported profitability barely moved: free cash flow narrowed from-$14.2M in FY2024 to-$5.5M in FY2025. Since operating margin stayed near-17.0% , that relief looks driven more by lower reinvestment and balance-sheet timing than by the core business turning profitable.
In FY2025, SG&A exceeded gross profit—
Liquidity is currently ample relative to the company’s size, with
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sunshine Biopharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sunshine Biopharma Inc scores -1.77, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.5M) relative to total liabilities ($7.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sunshine Biopharma Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Sunshine Biopharma Inc reported a net loss of $6.0M while operations used $5.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Sunshine Biopharma Inc generated $36.3M in revenue in fiscal year 2025. This represents an increase of 4.1% from the prior year.
Sunshine Biopharma Inc's EBITDA was -$5.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5.5% from the prior year.
Sunshine Biopharma Inc reported -$6.0M in net income in fiscal year 2025. This represents a decrease of 16.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Sunshine Biopharma Inc recorded an outflow of $5.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 61.2% from the prior year.
Sunshine Biopharma Inc held $9.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Sunshine Biopharma Inc's gross margin was 33.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.2 percentage points from the prior year.
Sunshine Biopharma Inc's operating margin was -17.2% in fiscal year 2025, reflecting core business profitability. This is down 0.5 percentage points from the prior year.
Sunshine Biopharma Inc's net profit margin was -16.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.7 percentage points from the prior year.
Sunshine Biopharma Inc's ROE was -25.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.1 percentage points from the prior year.
Capital Allocation
Sunshine Biopharma Inc invested $604K in research and development in fiscal year 2025. This represents a decrease of 35.3% from the prior year.
Sunshine Biopharma Inc repurchased no shares in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Sunshine Biopharma Inc invested $174K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 89.5% from the prior year.
SBFM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.3M | $36.3M+4.1% | $34.9M+44.7% | $24.1M+454.4% | $4.3M+1802.4% | $228K+219.9% | $71K+238.1% | $21K | $0 | $0 | $0-100.0% | $2K | $0 | $0 | $0 | $0 |
| Cost of Revenue | $24.6M | $24.1M-0.6% | $24.2M+53.6% | $15.8M+494.7% | $2.6M+2148.2% | $118K+355.9% | $26K+133.9% | $11K | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $10.7M | $12.3M+14.9% | $10.7M+27.9% | $8.3M+391.5% | $1.7M+1434.0% | $111K+142.7% | $46K+352.4% | $10K | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $238K | $604K-35.3% | $934K-49.7% | $1.9M+128.6% | $812K+20.8% | $672K+38801.0% | $2K-88.6% | $15K+18.8% | $13K | $0-100.0% | $33K+278.8% | $9K-97.4% | $327K+138.0% | $137K+7412.3% | $2K-98.7% | $143K |
| SG&A Expenses | $16.6M | $18.5M+12.1% | $16.5M+25.6% | $13.1M-54.3% | $28.7M+1025.1% | $2.6M+309.8% | $622K | N/A | $1.2M+35.8% | $857K | N/A | $782K | N/A | N/A | N/A | N/A |
| Operating Income | -$5.9M | -$6.2M-7.1% | -$5.8M-21.5% | -$4.8M+82.3% | -$27.0M-1006.5% | -$2.4M-323.0% | -$577K | N/A | -$1.2M-35.8% | -$857K | N/A | -$780K | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | $0-100.0% | $9K-93.6% | $137K+248.4% | $39K-88.0% | $329K+95.6% | $168K+45.0% | $116K-19.2% | $143K+36.9% | $105K+201.8% | $35K-88.7% | $307K+118.0% | $141K+2083.1% | $6K+407.5% | $1K | N/A |
| Income Tax | $271K | $22K+109.2% | -$235K-159.4% | $395K+69.4% | $233K | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$5.8M | -$6.0M-16.4% | -$5.1M-13.9% | -$4.5M+83.2% | -$26.7M | N/A | -$2.8M | N/A | -$2.2M-107.3% | -$1.0M | N/A | -$1.7M | N/A | N/A | N/A | N/A |
| EPS (Diluted) | — | N/A | -$7.32 | -$351.36 | -$1.76+63.0% | -$4.76 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SBFM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $30.1M-1.6% | $30.6M+11.8% | $27.3M-6.5% | $29.2M+1227.5% | $2.2M+110.7% | $1.0M+965.3% | $98K-91.4% | $1.1M+345.3% | $257K+299.8% | $64K-90.4% | $673K+369.4% | $143K+359.1% | $31K-76.8% | $135K+26.6% | $106K |
| Current Assets | $26.9M+3.4% | $26.0M+4.3% | $24.9M-8.9% | $27.3M+1143.8% | $2.2M+114.0% | $1.0M+1461.9% | $66K-94.0% | $1.1M+839.8% | $117K+100.5% | $58K+8.4% | $54K-62.4% | $143K+359.1% | $31K-76.8% | $135K+26.6% | $106K |
| Cash & Equivalents | $9.1M-5.8% | $9.7M-40.5% | $16.3M-25.4% | $21.8M+967.2% | $2.0M+106.6% | $990K+2344.1% | $41K-63.4% | $111K+2.8% | $108K+87.2% | $57K+13.1% | $51K-64.6% | $143K+359.1% | $31K-76.4% | $133K+118.5% | $61K |
| Inventory | $13.5M+19.5% | $11.3M+96.7% | $5.7M+74.3% | $3.3M+3014.0% | $106K+344.4% | $24K+49.4% | $16K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $3.5M-10.6% | $3.9M+51.6% | $2.6M+33.5% | $1.9M+24421.1% | $8K+307.0% | $2K+345.6% | $430 | $0 | $0 | N/A | $3K | $0 | N/A | N/A | N/A |
| Goodwill | N/A | $0 | $0 | $0 | $0 | N/A | N/A | $666K | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.0M-0.3% | $7.1M+15.0% | $6.1M-19.4% | $7.6M+282.5% | $2.0M-0.5% | $2.0M+140.0% | $834K-30.7% | $1.2M+44.7% | $831K+203.1% | $274K-78.4% | $1.3M+139.2% | $531K+1263.3% | $39K-39.5% | $64K+1774.4% | $3K |
| Current Liabilities | $6.4M+2.0% | $6.3M+13.7% | $5.6M-19.9% | $6.9M+7497.4% | $91K-91.3% | $1.1M+26.1% | $834K-8.7% | $912K+21.5% | $751K+174.0% | $274K-78.4% | $1.3M+139.2% | $531K | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $949K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $23.0M-2.0% | $23.5M+10.8% | $21.2M-1.9% | $21.6M+10118.0% | $212K+122.2% | -$955K-29.8% | -$735K-1219.0% | -$56K+90.3% | -$573K-173.4% | -$210K+64.9% | -$597K-54.0% | -$388K-4927.0% | -$8K-110.9% | $70K-31.6% | $103K |
| Retained Earnings | -$75.0M-8.7% | -$69.0M-8.0% | -$63.9M-7.6% | -$59.4M-81.9% | -$32.7M-61.5% | -$20.2M-16.0% | -$17.4M-10.5% | -$15.8M-15.8% | -$13.6M-8.3% | -$12.6M-38.5% | -$9.1M-22.3% | -$7.4M-35.2% | -$5.5M-83.0% | -$3.0M-30.9% | -$2.3M |
SBFM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.4M | -$5.3M+57.4% | -$12.5M-42.7% | -$8.8M-67.2% | -$5.2M-186.9% | -$1.8M-178.3% | -$657K | N/A | -$513K+5.7% | -$544K-73.0% | -$314K+63.8% | -$868K-61.1% | -$539K | N/A | -$393K-32.2% | -$297K |
| Capital Expenditures | $19K | $174K-89.5% | $1.7M+1914.6% | $82K-57.6% | $194K | $0-100.0% | $1K+38.5% | $860-95.4% | $19K+407.0% | $4K+8.1% | $3K-28.2% | $5K | $0 | N/A | N/A | N/A |
| Free Cash Flow | -$5.4M | -$5.5M+61.2% | -$14.2M-60.1% | -$8.9M-62.7% | -$5.4M-197.5% | -$1.8M-177.8% | -$658K | N/A | -$532K+2.8% | -$547K-72.3% | -$318K+63.6% | -$872K-62.0% | -$539K | N/A | N/A | N/A |
| Investing Cash Flow | -$184K | -$836K+57.7% | -$2.0M-201.7% | -$656K+95.5% | -$14.6M | $0+100.0% | -$1K+92.2% | -$15K-9.8% | -$14K+83.4% | -$84K-2342.8% | -$3K+99.4% | -$624K | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $8.5M | $4.7M-46.9% | $8.9M+161.0% | $3.4M-91.3% | $39.5M+1258.7% | $2.9M+80.6% | $1.6M+263.6% | $442K-16.2% | $528K-21.3% | $671K | N/A | $1.4M+114.9% | $651K | N/A | $465K+137.7% | $196K |
| Dividends Paid | N/A | N/A | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $0-100.0% | $3.1M+480.2% | $541K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SBFM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.8%+3.2pp | 30.6%-4.0pp | 34.6%-4.4pp | 39.0%-9.4pp | 48.4%-15.4pp | 63.8%+16.1pp | 47.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -17.2%-0.5pp | -16.7%+3.2pp | -19.9% | -621.3% | -1068.2% | -807.8% | N/A | N/A | N/A | N/A | -45683.7% | N/A | N/A | N/A | N/A |
| Net Margin | -16.5%-1.7pp | -14.7%+4.0pp | -18.7% | -615.4% | N/A | -3898.7% | N/A | N/A | N/A | N/A | -96774.5% | N/A | N/A | N/A | N/A |
| Return on Equity | -25.9%-4.1pp | -21.9%-0.6pp | -21.3%+102.4pp | -123.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -19.9%-3.1pp | -16.8%-0.3pp | -16.5%+75.0pp | -91.5% | N/A | -266.3% | N/A | -188.1%+215.9pp | -404.0% | N/A | -245.5% | N/A | N/A | N/A | N/A |
| Current Ratio | 4.17+0.1x | 4.11-0.4x | 4.48+0.5x | 3.94-20.1x | 24.07+23.1x | 0.98+0.9x | 0.08-1.1x | 1.21+1.1x | 0.16-0.1x | 0.21+0.2x | 0.04-0.2x | 0.27 | N/A | N/A | N/A |
| Debt-to-Equity | 0.310.0x | 0.300.0x | 0.29-0.1x | 0.35-9.1x | 9.41 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.91+0.9x | 0.03 |
| FCF Margin | -15.2%+25.5pp | -40.7%-3.9pp | -36.8% | -125.2% | -800.8% | -922.1% | N/A | N/A | N/A | N/A | -51079.5% | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Sunshine Biopharma Inc Ranks
Frequently Asked Questions
What is Sunshine Biopharma Inc's annual revenue?
Sunshine Biopharma Inc (SBFM) reported $36.3M in total revenue for fiscal year 2025. This represents a 4.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sunshine Biopharma Inc's revenue growing?
Sunshine Biopharma Inc (SBFM) revenue grew by 4.1% year-over-year, from $34.9M to $36.3M in fiscal year 2025.
Is Sunshine Biopharma Inc profitable?
No, Sunshine Biopharma Inc (SBFM) reported a net income of -$6.0M in fiscal year 2025, with a net profit margin of -16.5%.
What is Sunshine Biopharma Inc's EBITDA?
Sunshine Biopharma Inc (SBFM) had EBITDA of -$5.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Sunshine Biopharma Inc's gross margin?
Sunshine Biopharma Inc (SBFM) had a gross margin of 33.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sunshine Biopharma Inc's operating margin?
Sunshine Biopharma Inc (SBFM) had an operating margin of -17.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Sunshine Biopharma Inc's net profit margin?
Sunshine Biopharma Inc (SBFM) had a net profit margin of -16.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Sunshine Biopharma Inc's return on equity (ROE)?
Sunshine Biopharma Inc (SBFM) has a return on equity of -25.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sunshine Biopharma Inc's free cash flow?
Sunshine Biopharma Inc (SBFM) recorded an outflow of $5.5M in free cash flow during fiscal year 2025. This represents a 61.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sunshine Biopharma Inc's operating cash flow?
Sunshine Biopharma Inc (SBFM) recorded an outflow of $5.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sunshine Biopharma Inc's total assets?
Sunshine Biopharma Inc (SBFM) had $30.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sunshine Biopharma Inc's capital expenditures?
Sunshine Biopharma Inc (SBFM) invested $174K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sunshine Biopharma Inc spend on research and development?
Sunshine Biopharma Inc (SBFM) invested $604K in research and development during fiscal year 2025.
What is Sunshine Biopharma Inc's current ratio?
Sunshine Biopharma Inc (SBFM) had a current ratio of 4.17 as of fiscal year 2025, which is generally considered healthy.
What is Sunshine Biopharma Inc's debt-to-equity ratio?
Sunshine Biopharma Inc (SBFM) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sunshine Biopharma Inc's return on assets (ROA)?
Sunshine Biopharma Inc (SBFM) had a return on assets of -19.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sunshine Biopharma Inc's cash runway?
Based on fiscal year 2025 data, Sunshine Biopharma Inc (SBFM) had $9.1M in cash against an annual operating cash burn of $5.3M. This gives an estimated cash runway of approximately 21 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sunshine Biopharma Inc's Altman Z-Score?
Sunshine Biopharma Inc (SBFM) has an Altman Z-Score of -1.77, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sunshine Biopharma Inc's Piotroski F-Score?
Sunshine Biopharma Inc (SBFM) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sunshine Biopharma Inc's earnings high quality?
Sunshine Biopharma Inc (SBFM) reported a net loss of $6.0M while operations used $5.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Sunshine Biopharma Inc?
Sunshine Biopharma Inc (SBFM) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.